HGEN News and Press, Humanigen Inc. From 10/26/21

Earlier studies have shown the granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing effect of lenzilumab may benefit CMML patients with RAS pathway mutations Study is intended to build on evidence that certain CMML patients have mutations associated with hyper-pr...

Ten most promising treatments for COVID-19 identified by the European Commission’s independent experts as having “the highest potential impact on the pandemic” * European Commission’s independent panel of 10 experts across Europe created the list af...

An abstract showing tumor specific targeting at all known tumor sites in glioblastoma patients, with no normal tissue uptake of ifabotuzumab, from a Phase 1 study will be presented at EANM‘21 A Phase 1b study of ifabotuzumab in non-CNS solid tumors (such as breast, colorect...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that the Company’s Board of Directors (the “Boardȁ...

Baseline C-reactive Protein (CRP) <150 mg/L identified as the strongest predictor of response to lenzilumab in hospitalized COVID-19 patients In this population age <85 years, lenzilumab improved likelihood of survival without ventilation by 3-fold and reduced mortality by 2...

Overall analysis demonstrates treatment with lenzilumab may result in both clinical and economic benefits in the majority of hospitalized patients Potential clinical and economic benefits are greater in certain patient populations Humanigen, Inc. (Nasdaq: HGEN) (“...

Program designed to fulfill requests from healthcare providers for access to lenzilumab, for patients with unmet medical needs Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune ...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that management will present and participate at multiple virtual investor c...

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced it has submitted all the planned modules as well as a ri...

Lenzilumab significantly improved the likelihood of survival without ventilation (SWOV) by 54% versus standard treatment in hospitalized patients with COVID-19 pneumonia IDWeek is the premier global scientific meeting that brings together infectious disease specialists from the In...